The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Markers of Response for the Antiangiogenic Agent Bevacizumab
Abstract
Bevacizumab is the first antiangiogenic therapy proven to slow metastatic disease progression in patients with cancer. Although it has changed clinical practice, some patients do not respond or gradually develop resistance, resulting in rather modest gains in terms of overall survival. A major challenge is to develop robust biomarkers that can guide selection of patients for whom bevacizumab therapy is most beneficial. Here, we discuss recent progress in finding such markers, including the first results from randomized phase III clinical trials evaluating the efficacy of bevacizumab in combination with comprehensive biomarker analyses. In particular, these studies suggest that circulating levels of short vascular endothelial growth factor A (VEGF-A) isoforms, expression of neuropilin-1 and VEGF receptor 1 in tumors or plasma, and genetic variants in VEGFA or its receptors are strong biomarker candidates. The current challenge is to expand this first set of markers and to validate it and implement it into clinical practice. A first prospective biomarker study known as MERiDiAN, which will treat patients stratified for circulating levels of short VEGF-A isoforms with bevacizumab and paclitaxel, is planned and will hopefully provide us with new directions on how to treat patients more efficiently.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Self-citationAngiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,482
Self-citationPaclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Basic and Therapeutic Aspects of Angiogenesis
Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771
Self-citationYang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
Self-citationVEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402
Robert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Lambrechts, D., Storkebaum, E., Morimoto, M., Del-Favero, J., Desmet, F., Marklund, S. L., Wyns, S., Thijs, V., Andersson, J., van Marion, I., et al. (2003) · Nature Genetics · doi:10.1038/ng1211 · Cited by 860
Self-citationTumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849
Mazzone, M., Dettori, D., Leite de Oliveira, R., Loges, S., Schmidt, T., Jonckx, B., Tian, Y.-M., Lanahan, A. A., Pollard, P., Ruiz de Almodovar, C., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.020 · Cited by 812
Self-citationEscudier, B., Bellmunt, J., Négrier, S., Bajetta, E., Melichar, B., Bracarda, S., Ravaud, A., Golding, S., Jethwa, S., & Sneller, V. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7849 · Cited by 800
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1
Autiero, M., Waltenberger, J., Communi, D., Kranz, A., Moons, L., Lambrechts, D., Kroll, J., Plaisance, S., De Mol, M., Bono, F., et al. (2003) · Nature Medicine · doi:10.1038/nm884 · Cited by 773
Self-citationCrawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., Kaminker, J., & Ferrara, N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.004 · Cited by 611
Schneider, B. P., Wang, M., Radovich, M., Sledge, G. W., Badve, S., Thor, A., Flockhart, D. A., Hancock, B., Davidson, N., Gralow, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1612 · Cited by 604
The multifaceted circulating endothelial cell in cancer: towards marker and target identification
Bertolini, F., Shaked, Y., Mancuso, P., & Kerbel, R. S. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1971 · Cited by 575
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Fischer, C., Mazzone, M., Jonckx, B., & Carmeliet, P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2524 · Cited by 568
Self-citationBlocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth
Pan, Q., Chanthery, Y., Liang, W.-C., Stawicki, S., Mak, J., Rathore, N., Tong, R. K., Kowalski, J., Yee, S. F., Pacheco, G., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.10.018 · Cited by 532
Batchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520
Hull, J. (2000) · Thorax · doi:10.1136/thorax.55.12.1023 · Cited by 515
Willett, C. G., Duda, D. G., di Tomaso, E., Boucher, Y., Ancukiewicz, M., Sahani, D. V., Lahdenranta, J., Chung, D. C., Fischman, A. J., Lauwers, G. Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1771 · Cited by 508
Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y., Adinin, R., Overman, M. J., Valero, V., Wen, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8252 · Cited by 485
Van Cutsem, E., de Haas, S., Kang, Y.-K., Ohtsu, A., Tebbutt, N. C., Ming Xu, J., Peng Yong, W., Langer, B., Delmar, P., Scherer, S. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9824 · Cited by 477
Self-citationZhu, A. X., Sahani, D. V., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Catalano, O. A., Sindhwani, V., Blaszkowsky, L. S., Yoon, S. S., Lahdenranta, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9908 · Cited by 477
A vascular niche and a VEGF–Nrp1 loop regulate the initiation and stemness of skin tumours
Beck, B., Driessens, G., Goossens, S., Youssef, K. K., Kuchnio, A., Caauwe, A., Sotiropoulou, P. A., Loges, S., Lapouge, G., Candi, A., et al. (2011) · Nature · doi:10.1038/nature10525 · Cited by 467
Self-citationRole and Therapeutic Potential of VEGF in the Nervous System
Ruiz de Almodovar, C., Lambrechts, D., Mazzone, M., & Carmeliet, P. (2009) · Physiological Reviews · doi:10.1152/physrev.00031.2008 · Cited by 448
Self-citationDynamic contrast-enhanced MRI in clinical trials of antivascular therapies
O'Connor, J. P. B., Jackson, A., Parker, G. J. M., Roberts, C., & Jayson, G. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.2 · Cited by 348
Dowlati, A., Gray, R., Sandler, A. B., Schiller, J. H., & Johnson, D. H. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1154 · Cited by 263
Loges, S., Schmidt, T., & Carmeliet, P. (2010) · Genes & Cancer · doi:10.1177/1947601909356574 · Cited by 257
Self-citationIncorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2012) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e3182547170 · Cited by 244
Price, T. J., Hardingham, J. E., Lee, C. K., Weickhardt, A., Townsend, A. R., Wrin, J. W., Chua, A., Shivasami, A., Cummins, M. M., Murone, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5520 · Cited by 209
Rudge, J. S., Holash, J., Hylton, D., Russell, M., Jiang, S., Leidich, R., Papadopoulos, N., Pyles, E. A., Torri, A., Wiegand, S. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708865104 · Cited by 203
Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies
Bottsford-Miller, J. N., Coleman, R. L., & Sood, A. K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.9242 · Cited by 199
Polymorphisms of KDRGene Are Associated With Coronary Heart Disease
Wang, Y., Zheng, Y., Zhang, W., Yu, H., Lou, K., Zhang, Y., Qin, Q., Zhao, B., Yang, Y., & Hui, R. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.04.074 · Cited by 197
Hegde, P. S., Jubb, A. M., Chen, D., Li, N. F., Meng, Y. G., Bernaards, C., Elliott, R., Scherer, S. J., & Chen, D. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2535 · Cited by 193
Self-citationLambrechts, D., Claes, B., Delmar, P., Reumers, J., Mazzone, M., Yesilyurt, B. T., Devlieger, R., Verslype, C., Tejpar, S., Wildiers, H., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70231-0 · Cited by 187
Self-citationGoede, V, Coutelle, O., Neuneier, J., Reinacher-Schick, A., Schnell, R., Koslowsky, T. C., Weihrauch, M. R., Cremer, B., Kashkar, H., Odenthal, M., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605925 · Cited by 186
Schultheis, A. M., Lurje, G., Rhodes, K. E., Zhang, W., Yang, D., Garcia, A. A., Morgan, R., Gandara, D., Scudder, S., Oza, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0351 · Cited by 182
Self-citationGrothey, A., Hedrick, E. E., Mass, R. D., Sarkar, S., Suzuki, S., Ramanathan, R. K., Hurwitz, H. I., Goldberg, R. M., & Sargent, D. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8099 · Cited by 171
Cascone, T., Herynk, M. H., Xu, L., Du, Z., Kadara, H., Nilsson, M. B., Oborn, C. J., Park, Y.-Y., Erez, B., Jacoby, J. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42405 · Cited by 164
Xu, L., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Chung, D. C., Lauwers, G. Y., Samuel, R., Shellito, P., Czito, B. G., Lin, P.-C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2099 · Cited by 161
Bagri, A., Tessier‐Lavigne, M., & Watts, R. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0563 · Cited by 154
Horn, L., Dahlberg, S. E., Sandler, A. B., Dowlati, A., Moore, D. F., Murren, J. R., & Schiller, J. H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7545 · Cited by 150
Boige, V., Malka, D., Bourredjem, A., Dromain, C., Baey, C., Jacques, N., Pignon, J., Vimond, N., Bouvet-Forteau, N., de Baère, T., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0465 · Cited by 135
Nikolinakos, P. G., Altorki, N. K., Yankelevitz, D. F., Tran, H. T., Yan, S., Rajagopalan, D., Bordogna, W., Ottesen, L. H., & Heymach, J. V. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2533 · Cited by 118
Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?
Cutsem, E. V., Lambrechts, D., Prenen, H., Jain, R. K., & Carmeliet, P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2701 · Cited by 113
Self-citationZhang, W. W., Cortes, J. E., Yao, H., Zhang, L., Reddy, N. G., Jabbour, E. J., Kantarjian, H. M., & Jones, D. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.4076 · Cited by 112
Kang, Y., Ohtsu, A., Cutsem, E. V., Rha, S. Y., Sawaki, A., Park, S., Lim, H. Y., Wu, J., Langer, B., & Shah, M. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.18_suppl.lba4007 · Cited by 110
Baar, J., Silverman, P., Lyons, J. A., Fu, P., Abdul‐Karim, F. W., Ziats, N. P., Wasman, J. K., Hartman, P. H., Jesberger, J. A., Dumadag, L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2917 · Cited by 103
Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer
Jubb, A. M., Miller, K. D., Rugo, H. S., Harris, A. L., Chen, D., Reimann, J. D., Cobleigh, M., Schmidt, M., Langmuir, V. K., Hillan, K. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1791 · Cited by 103
Gerger, A., El-Khoueiry, A. B., Zhang, W., Yang, D., Singh, H., Bohanes, P. O., Ning, Y., Winder, T., LaBonte, M. J., Wilson, P. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1115 · Cited by 92
Self-citationLoupakis, F., Cremolini, C., Fioravanti, A., Orlandi, P., Salvatore, L., Masi, G., Desidero, T. D., Canu, B., Schirripa, M., Frumento, P., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.85 · Cited by 89
Kaseb, A. O., Garrett-Mayer, E. S., Morris, J. S., et al. (2012) · Oncology · doi:10.1159/000335963 · Cited by 87
High-grade glioma before and after treatment with radiation and Avastin: Initial observations
Fischer, I., Cunliffe, C. H., Bollo, R. J., Raza, S., Monoky, D., Chiriboga, L. A., Parker, E. C., Golfinos, J. G., Kelly, P. J., Knopp, E. A., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-042 · Cited by 81
Koutras, A. K., Antonacopoulou, A. G., Eleftheraki, A. G., Dimitrakopoulos, F.-I. D., Koumarianou, A. A., Varthalitis, I. I., Fostira, F., Sgouros, J., Briasoulis, E. C., Bournakis, E., et al. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2011.37 · Cited by 79
Loupakis, F., Ruzzo, A., Salvatore, L., Cremolini, C., Masi, G., Frumento, P., Schirripa, M., Catalano, V., Galluccio, N., Canestrari, E., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-247 · Cited by 74
Genetics, epigenetics and pharmaco‐(epi)genomics in angiogenesis
Buysschaert, I., Schmidt, T., Roncal, C., Carmeliet, P., & Lambrechts, D. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00515.x · Cited by 71
Self-citationHansen, T. F., Christensen, R. D., Andersen, R. F., Spindler, K. G., Johnsson, A., & Jakobsen, A. K. M. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1382-6 · Cited by 61
Smerdel, M. P., Steffensen, K. D., Waldstrøm, M., Brandslund, I., & Jakobsen, A. K. M. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.03.018 · Cited by 53
Weickhardt, A. J., Williams, D., Lee, C., Simes, J. R., Murone, C., Wilson, K., Cummins, M. M., Asadi, K., Price, T. J., Mariadason, J. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3531 · Cited by 53
Meyerhardt, J. A., Ancukiewicz, M., Abrams, T. A., Schrag, D., Enzinger, P. C., Chan, J. A.-W., Kulke, M. H., Wolpin, B. M., Goldstein, M., Blaszkowsky, L. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038231 · Cited by 51
Refocusing the War on Cancer: The Critical Role of Personalized Treatment
Potti, A., Schilsky, R. L., & Nevins, J. R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000643 · Cited by 38
Phase II trial of neoadjuvant temozolomide in resectable melanoma patients
Shah, G., Socci, N. D., Gold, J. S., Wolchok, J. D., Carvajal, R. D., Panageas, K., Viale, A. J., Brady, M. S., Coit, D. G., & Chapman, P. B. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp593 · Cited by 36
Inhibiting Angiogenesis in Breast Cancer: The Beginning of the End or the End of the Beginning?
Rugo, H. S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.5492 · Cited by 31
Miles, D. W., de Haas, S., Dirix, L. Y., Chan, A., Pivot, X. B., Tomczak, P., Provencher, L., Delmar, P., & Scherer, S. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-p2-16-04 · Cited by 26
Self-citationLieu, C. H., Tran, H., Jiang, Z., Mao, M., Overman, M. J., Eng, C., Morris, J. S., Ellis, L. M., Heymach, J. V., & Kopetz, S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3533 · Cited by 21
Tolaney, S. M., Duda, D. G., Boucher, Y., Goel, S., Martin, J. D., Ancukiewicz, M., Potler, H., Incio, J., Ligibel, J. A., Isakoff, S. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.1026 · Cited by 14
Miles, D. W., de Haas, S. L., Romieu, G., et al. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70916-9 · Cited by 5
Muggia, F. M., Safra, T., Borgato, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.5064 · Cited by 5
Cited by
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Goel, H. L., & Mercurio, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3627 · Cited by 1,253
Garcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O. L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102017 · Cited by 1,159
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti, J., Loges, S., Dimmeler, S., & Carmeliet, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70212 · Cited by 591
Self-citation
Metadata
- Authors
- Lambrechts, D., Lenz, H.-J., de Haas, S., Carmeliet, P., & Scherer, S. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-03-20
- Volume
- 31
- Issue
- 9
- Pages
- 1219-1230
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2111391096
- Cited by
- 332
- References
- 84
- FWCI
- 23.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.